Related Experiment Video
Updated: Apr 10, 2026
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction
Rui Zhang1, Chao Lan2, Hui Pei3
1Department of emergency, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe Road, Zhengzhou, Henan, 450052, China. ruizhang0001@126.com.
Background:
With its high morbidity and mortality, acute myocardial infarction (AMI) places a major burden on society and on individual patients. Correct, early correct diagnosis is crucial to the management of AMI.
Methods:
In this study, the expression of circulating miR-486 and miR-150 was investigated in AMI patients and the two miRNAs were evaluated as potential biomarkers for AMI. Plasma samples from 110 patients with AMI (65 patients with ST-segment elevation myocardial infarction (STEMI) and 45 patients with non-ST-segment elevation myocardial infarction (NSTEMI)) and 110 healthy adults were collected. Circulating levels of miR-486 and miR-150 were detected using quantitative real-time PCR in plasma samples.
Results:
Results showed that the levels of miR-486 and miR-150 were significantly higher in AMI patients than in healthy controls. Receiver operating characteristic (ROC) curve analyses indicated that the two plasma miRNAs were of significant diagnostic value for AMI, especially NSTEMI. The combined ROC analysis revealed an AUC value of 0.771 in discriminating AMI patients from healthy controls and an AUC value of 0.845 in discriminating NSTEMI patients from healthy controls.
Conclusion:
Results indicated that the levels of circulating miR-486 and miR-150 are associated with AMI. They may be novel and powerful biomarkers for AMI, especially for NSTEMI.
Insights
Circulating miR-486 and miR-150 levels are elevated in acute myocardial infarction (AMI) patients. These microRNAs show promise as novel diagnostic biomarkers for AMI, particularly for non-ST-segment elevation myocardial infarction (NSTEMI).
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiology
Background:
- Acute myocardial infarction (AMI) presents a significant health burden due to high morbidity and mortality.
- Early and accurate diagnosis is critical for effective AMI management.
Purpose of the Study:
- To investigate the expression of circulating miR-486 and miR-150 in AMI patients.
- To evaluate miR-486 and miR-150 as potential diagnostic biomarkers for AMI.
Main Methods:
- Plasma samples were collected from 110 AMI patients (STEMI and NSTEMI) and 110 healthy controls.
- Quantitative real-time PCR was used to detect circulating levels of miR-486 and miR-150.
Main Results:
- Circulating levels of miR-486 and miR-150 were significantly higher in AMI patients compared to healthy controls.
- Receiver operating characteristic (ROC) curve analyses demonstrated significant diagnostic value for these miRNAs in AMI, especially NSTEMI.
- Combined ROC analysis showed an AUC of 0.771 for AMI and 0.845 for NSTEMI discrimination.
Conclusions:
- Elevated circulating miR-486 and miR-150 levels are associated with AMI.
- These microRNAs represent potential novel and powerful biomarkers for the diagnosis of AMI, particularly NSTEMI.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:21Myocarditis I: Introduction
01:30Acute Coronary Syndrome I: Introduction